A phase II study of oral etoposide in elderly patients with small cell lung cancer.

E F Smit, D N Carney, P Harford, D T Sleijfer, P E Postmus

Department of Pulmonary Diseases, State University Hospital Groningen, The Netherlands.

Thirty five previously untreated patients with small cell lung cancer older than 70 years were treated with oral etoposide (800 mg/m2 over five consecutive days) every four weeks. Twenty two patients had extensive disease and 13 limited disease. The overall response rate was 71%. The median survival for patients with limited diseases was 16 (range 6-32) months and for patients with extensive disease nine (range 4-17) months. There was mild haematological toxicity and alopecia but no major toxicity. It is concluded that etoposide in this dose regimen is an effective and well tolerated treatment for elderly patients with small cell lung cancer.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Niell, H. B., Herndon, J. E. II, Miller, A. A., Watson, D. M., Sandler, A. B., Kelly, K., Marks, R. S., Perry, M. C., Ansari, R. H., Otterson, G., Ellerton, J., Vokes, E. E., Green, M. R. (2005). Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732. JCO 23: 3752-3759 [Abstract] [Full Text]  
• Rossi, A., Maione, P., Colantuoni, G., Guerriero, C., Ferrara, C., Del Gaizo, F., Nicolella, D., Gridelli, C. (2005). Treatment of Small Cell Lung Cancer in the Elderly. The Oncologist 10: 399-411 [Abstract] [Full Text]  
• Hurria, A., Kris, M. G. (2003). Management of Lung Cancer in Older Adults. CA Cancer J Clin 53: 325-341 [Abstract] [Full Text]  
• Osterlind, K. (2001). Chemotherapy in small cell lung cancer. Eur Respir J 18: 1026-1043 [Abstract] [Full Text]  
• Fokkema, E., Groen, H. J.M., Bauer, J., Uges, D. R.A., Weil, C., Smith, I. E. (1999). Phase II Study of Oral Platinum Drug JM216 as First-Line Treatment in Patients With Small-Cell Lung Cancer. JCO 17: 3822-3827 [Abstract] [Full Text]